Oncotarget

Reviews:

Type I insulin-like growth factor receptor signaling in hematological malignancies

Deeksha Vishwamitra, Suraj Konnath George, Ping Shi, Ahmed O. Kaseb and Hesham M. Amin _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:1814-1844. https://doi.org/10.18632/oncotarget.12123

Metrics: PDF 2872 views  |   HTML 5692 views  |   ?  


Abstract

Deeksha Vishwamitra1, Suraj Konnath George1, Ping Shi2, Ahmed O. Kaseb3 and Hesham M. Amin1,4

1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2 State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

3 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA

Correspondence to:

Hesham M. Amin, email:

Keywords: IGF-IR; plasma cell myeloma; leukemia; lymphoma

Received: January 21, 2016 Accepted: September 12, 2016 Published: September 19, 2016

Abstract

The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12123